Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy [Yahoo! Finance]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
PBGENE-PMM shifted heteroplasmy by eliminating mutant m.3243 mitochondrial DNA (mtDNA) while repopulating wild type mtDNA, leading to improved mitochondrial function in cells Precision expects to submit a CTA and/or IND for PBGENE-PMM in 2025 DURHAM, N.C., March 19, 2024 BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced a poster presentation highlighting new data for the Company's PBGENE-PMM program, evaluating an ARCUS nuclease as a potential treatment for m.3243-associated primary mitochondrial myopathy (PMM). These data are being presented at the Mitochondrial Medicine – Therapeutic Development Annual Conference, being held from March 18-20, 2024 in Hinxton, UK. "Today's data from our PBGENE-PMM program further validate our work with ARCUS and c
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail TherapeuticsBusiness Wire
- Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? [Yahoo! Finance]Yahoo! Finance
- iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S. [Yahoo! Finance]Yahoo! Finance
- iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.Business Wire
DTIL
Earnings
- 3/27/24 - Miss
DTIL
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- DTIL's page on the SEC website